These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1396108)

  • 21. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The implementation of buprenorphine/naloxone in college health practice.
    DeMaria PA; Patkar AA
    J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine in combination with naloxone at a ratio of 15:1 does not enhance antinociception from buprenorphine in healthy cats.
    Slingsby LS; Murrell JC; Taylor PM
    Vet J; 2012 Jun; 192(3):523-4. PubMed ID: 22030474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naloxone suppresses buprenorphine stimulation of plasma prolactin.
    Mendelson JH; Mello NK; Teoh SK; Lloyd-Jones JG; Clifford JM
    J Clin Psychopharmacol; 1989 Apr; 9(2):105-9. PubMed ID: 2723127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
    Shannon HE; Cone EJ; Gorodetzky CW
    J Pharmacol Exp Ther; 1984 Jun; 229(3):768-74. PubMed ID: 6547177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abuse liability assessment of buprenorphine-naloxone combinations.
    Bigelow GE; Preston KL; Liebson IA
    NIDA Res Monogr; 1987; 76():145-9. PubMed ID: 2449616
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of buprenorphine in buprenorphine-maintained volunteers.
    Strain EC; Walsh SL; Preston KL; Liebson IA; Bigelow GE
    Psychopharmacology (Berl); 1997 Feb; 129(4):329-38. PubMed ID: 9085402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of buprenorphine and methadone in methadone-maintained subjects.
    Walsh SL; June HL; Schuh KJ; Preston KL; Bigelow GE; Stitzer ML
    Psychopharmacology (Berl); 1995 Jun; 119(3):268-76. PubMed ID: 7675960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naloxone reversal of buprenorphine-induced respiratory depression.
    Gal TJ
    Clin Pharmacol Ther; 1989 Jan; 45(1):66-71. PubMed ID: 2491980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.
    Comer SD; Walker EA; Collins ED
    Psychopharmacology (Berl); 2005 Oct; 181(4):664-75. PubMed ID: 16025322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of naloxone, diprenorphine, buprenorphine and etorphine on unpunished and punished food-reinforced responding in the squirrel monkey.
    DeRossett SE; Holtzman SG
    J Pharmacol Exp Ther; 1984 Mar; 228(3):669-75. PubMed ID: 6707916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.